An internal investigation by SciClone Pharmaceuticals Inc. uncovered evidence of sales and marketing activities that might violate the Foreign Corrupt Practices Act, the company said Tuesday. SciClone previously disclosed that a special committee of directors was investigating operations in China for compliance with the law, which bars foreign bribery.
via SciClone Reports Possible FCPA Violations To DOJ, SEC – Corruption Currents – WSJ.
